Dr. John's Health Matters
Welcome to Dr. John's Health Matters blog.
The articles posted here are from various sources who are duly acknowledged. I would appreciate being immediately notified, if any copywritten material needs to be removed. This blog is not intended to replace the qualified advice of a licensed health practitioner. Readers should exercise their own judgment. Enjoy, subscribe, participate and tell others :)
Following:
Tamoxifen ups second breast cancer risk →
Aug 30, 2009 (Presstv.com)—While tamoxifen has long been prescribed to treat breast cancer, a new study links the drug to the development of a second tumor in consumers.
Despite the development of many newer drugs, tamoxifen — which prevents tumors from being fuelled by the sex hormone estrogen — has still remained the gold standard in treating hormone sensitive tumors.
According to the study published in Cancer Research, the long-term use of the common breast cancer drug places the consumer at an increased risk of developing a more aggressive, difficult-to-treat tumor.
Tamoxifen lowers the reoccurrence risk of estrogen-positive breast cancers by 60%.
It, however, increases the risk of developing a second ER negative (estrogen receptor negative) tumor in the opposite breast by 440%.
Scientists urged women to continue taking the medication despite the findings of their study, adding that the odds of developing a second tumor is very low in these individuals.
PKH/HGH
